Nafamostat Efficacy in Phase 3 Registrational CRRT Study (NCT06150742)
A Randomized, Placebo-controlled, Double-blind, Multi-center Study of the Safety and Efficacy of Niyad in Patients Undergoing Continuous Renal Replacement Therapy (CRRT) Who Cannot Tolerate Heparin or Are at a Higher Risk for Bleeding
🩺 Plain-English Summary (8th-Grade Level)
A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.
Who can join: Review the eligibility criteria below.
Location: University of California Los Angeles — Los Angeles, California
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- University of California Los Angeles — Los Angeles, California
- AdventHealth — Orlando, Florida
- Henry Ford Health — Detroit, Michigan
- University of New Mexico — Albuquerque, New Mexico
- Northwell Health — Great Neck, New York
- Mount Sinai — New York, New York
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- Baylor University Medical Center — Dallas, Texas
📞 Contact the Study Coordinator
Phone: (647) 724-5709
Email: nazneen.patel@clinchoice.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Kidney Injury
- An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury — Chicago, Illinois
- Acute Kidney Injury Genomics and Biomarkers in TAVR Study — Dallas, Texas
- Evaluation of UDP-glucose as a Urinary Biomarker for Early Detection of Cardiac Surgery-associated Pediatric Acute Kidney Injury — Boston, Massachusetts
- Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage — Oklahoma City, Oklahoma
- Proactive Prescription-based Fluid Management vs Usual Care in Critically Ill Patients on Kidney Replacement Therapy — Montreal, Quebec
- A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" — Birmingham, Alabama
Explore by condition: All Acute Kidney Injury clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.